Lee Pharmaceuticals, Inc. – ‘1-K’ for 12/31/22

On: Thursday, 4/27/23, at 11:59am ET · For: 12/31/22 · Accession #: 1393905-23-186

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/27/23 Lee Pharmaceuticals, Inc. 1-K 12/31/22 3:484K Empire Stock Transf… Inc

Document/Exhibit Description Pages Size 1: 1-K Annual Report or Special Financial Report -- HTML 5K primary_doc.xml 2: PART II Special Financial Report HTML 361K 3: EX1K-11 CONSENT Auditors Consent HTML 5K

1-K: Filer Information

Issuer CIK

0000058411

Issuer CCC

XXXXXXXX

Is filer a shell company?

Yes

Is the electronic copy of an official filing submitted in paper format?

File Number

Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination?

Yes

Successor File Number

Is this a LIVE or TEST Filing?

LIVE

TEST

Would you like a Return Copy?

Period

12/31/22

Submission Contact Information

Name

Phone

E-Mail Address

Notify via Filing Website only?

1-K: Tab 1 Notification

This Form 1-K is to provide an

Annual Report Radio button checked

Special Financial Report for the fiscal year

Fiscal Year End

12/31/22

Exact name of issuer as specified in the issuer's charter

Lee Pharmaceuticals, Inc.

CIK

0000058411

Jurisdiction of Incorporation / Organization

COLORADO

I.R.S. Employer Identification Number

95-2680312

Address of Principal Executive Offices

Address 1

11 N WATER STREET

Address 2

City

MOBILE

State/Country

NEVADA

Mailing Zip/ Postal Code

36602

Phone

678-999-6242

Title of each class of securities issued pursuant to Regulation A

Common Stock

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Checkbox not checked The following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement

024-11991

Date of qualification of the offering statement

1/17/23

Date of commencement of the offering

1/19/23

Amount of securities qualified to be sold in the offering

5000000000

Amount of securities sold in the offering

25000000

Price per security

$ 0.0100

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 250000.00

The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders

$ 0.00

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider

Underwriters - Fees

Sales Commissions - Name of Service Provider

Sales Commissions - Fee

Finders' Fees - Name of Service Provider

Finders' Fees - Fees

Accounting or Audit - Name of Service Provider

Accounting or Audit - Fees

Legal - Name of Service Provider

JDT Legal

PLLC

Legal - Fees

$ 15000.00

Promoters - Name of Service Provider

Promoters - Fees

Blue Sky Compliance - Name of Service Provider

Blue Sky Compliance - Fees

CRD Number of any broker or dealer listed

Net proceeds to the issuer

$ 235000.00

Clarification of responses (if necessary)

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/13/22 Lee Pharmaceuticals, Inc. 1-A 8:1.3M Empire Stock Transf… Inc

Lee Pharmaceuticals, Inc. – ‘1-K’ for 12/31/22

On: Thursday, 4/27/23, at 11:59am ET · For: 12/31/22 · Accession #: 1393905-23-186

1 Reference: To: Lee Pharmaceuticals, Inc. – ‘1-A’ on 9/13/22

Annual Report or Special Financial Report — Form 1-K — Regulation A

Filing Table of Contents

‘1-K’ — Annual Report or Special Financial Report — primary_doc.xml

This ‘1-K’ Document is an XML Data File that may be rendered in various formats:

1-K: Filer Information

Submission Contact Information

1-K: Tab 1 Notification

Address of Principal Executive Offices

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Fees in connection with this offering and names of service providers.

1 Previous Filing that this Filing References

Lee Pharmaceuticals, Inc. – ‘1-K’ for 12/31/22

On: Thursday, 4/27/23, at 11:59am ET · For: 12/31/22 · Accession #: 1393905-23-186

1 Reference: To: Lee Pharmaceuticals, Inc. – ‘1-A’ on 9/13/22

Annual Report or Special Financial Report — Form 1-K — Regulation AFiling Table of Contents

‘1-K’ — Annual Report or Special Financial Report — primary_doc.xml

This ‘1-K’ Document is an XML Data File that may be rendered in various formats:

1-K: Filer Information

Submission Contact Information

1-K: Tab 1 Notification

Address of Principal Executive Offices

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Fees in connection with this offering and names of service providers.

1 Previous Filing that this Filing References

Annual Report or Special Financial Report — Form 1-K — Regulation A

Filing Table of Contents